All lobbying filings
ALNYLAM PHARMACEUTICALS, INC.
Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$470,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Massachusetts
Lobbyists on this filing
2
-
CURTIS RHYNEPreviously held: Rep. Virginia Foxx (2008-2009), House Republican Study Committee (2009-2014), Rep. Richard Hudson (2014-2017), Rep. George Holding (2017-2020)
-
MARGARET HERMANPreviously held: Legislative Aide, Senator Mark Warner (June 2017-May 2019); Legislative Assistant, Rep. Mikie Sherrill (May 2019-Jan. 2020); Senior LA, Rep. Dan Kildee (Jan. 2020-Dec. 2022)
Government bodies contacted
2
Lobbying activity
3
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing
Issues relating to supply chain tariffs
Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.